texas oncology more breakthroughs. more victories

Jeff Yorio, M.D.

Jeff Yorio, M.D. Photo

Provider Type: Physician

Specialties:
Board Certifications:
  • Hematology
  • Internal Medicine
  • Medical Oncology

Downloads

General Summary

Dr. Yorio is a native Texan, born and raised in Burleson near Fort Worth. He is board certified in medical oncology, hematology, and internal medicine. He serves as the Central Texas Research Site Leader for Texas Oncology and Sarah Cannon Research Institute. He is actively involved in clinical trial research for melanoma, renal cell carcinoma, prostate cancer, bladder cancer, and head & neck cancer with publications in the areas of melanoma, renal cell cancer, lung cancer and colorectal cancer. He has served as a national and local principal investigator for multiple clinical trials and he strives to bring cutting edge treatments and new research to patients here in Austin.

Dr. Yorio and his wife met as undergraduate students at The University of Texas, and like many Longhorns, wanted to make Austin their lifelong home. He enjoys spending time with his wife and two amazing children, playing guitar & tennis, jogging, skiing, and paddleboarding. He and his family are also avid Texas Longhorn fans.

Education

  • Fellowship in Medical Oncology and Hematology
    UT MD Anderson Cancer Center, Houston, TX
  • Residency in Internal Medicine
    UT Southwestern Medical Center, Dallas, TX
  • Doctor of Medicine with Distinction in Research
    The University of Texas Southwestern Medical Center, Dallas, TX
  • Bachelor of Science in Advertising
  • The University of Texas, Austin, TX 

Accolades & Memberships

Affiliations
  • Central Texas Site Research Leader, Sarah Cannon Research Institute at Texas Oncology
  • Chief of Hematology-Oncology Service, Seton Medical Center Austin
  • Associate Chair, Genitourinary Research Committee, Sarah Cannon Research Institute
  • Developmental Therapeutics Research Committee Member, Sarah Cannon Research Institute
  • Chair of Marketing Committee, Texas Oncology Austin
  • Appointed Member of Ops Board and Executive Committee, Texas Oncology Austin
  • American Society of Clinical Oncology Member
  • ​Travis County Medical Society Member
Awards
  • Austin’s Top Doctors, Oncology & Hematology, Austin Monthly, 2020-2023
  • Texas Rising Stars, Oncology & Hematology, SuperDoctors, 2021-2023
  • Shining Star Award, U.S. Oncology Research, 2022
  • Health Care Innovation Award, Health Tech Austin, 2020
  • Rising Star Award, U.S. Oncology Research, 2019
  • Jesse H. Jones Fellowship in Cancer Education, UT MD Anderson, 2013
  • LBJ Clinical Fellow of the Year, UT MD Anderson, 2013
  • Educational Grant, National Comprehensive Cancer Network Fellow Recognition Program at the NCCN 18th Annual Conference, 2013
  • Outstanding Clinical Research Award, UT Southwestern Housestaff, 2011
  • Outstanding Clinical Research Award, Eastern Cooperative Oncology Group (ECOG) Young Investigator’s Symposium, 2008

Publications

Show all Publications
  • Combined Lenvatinib and Pembrolizumab As Salvage Therapy in Advanced Adrenal Cortical Carcinoma

    Journal of Immunotherapy of Cancer, 2020

  • Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study

    Lancet, 2019

  • Phase 3 Study of Pembrolizumab Plus Chemoradiation (CRT) vs CRT Alone for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

    Society for Immunotherapy of Cancer (SITC) 2017 Conference, 2017

  • An Interprofessionally Developed Geriatric Oncology Curriculum for Hematology-Oncology Fellows

    Journal of Geriatric Oncology, 2015

  • A Case of Vemurafenib-Induced Sweet’s Syndrome

    The Journal of Dermatology, 2014

  • Treatment Decisions in a Man with Hodgkin Lymphoma and Guillian-Barre Syndrome: A Case Report

    Journal of Medical Case Reports, 2014

  • Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III Non-Small Cell Lung Cancer

    Clinical Lung Cancer, 2013

  • Rare Though Not Mutually Exclusive: a Report of Three Cases of Concomitant Kras and Braf Mutation and a Review of the Literature

    Journal of Cancer, 2013

  • Toxicities and Outcomes in Metastatic Melanoma Patients Treated with Ipilimumab and Braf Inhibitors

    Society for Melanoma Research 2013 Congress, 2013

  • Improving the Care of Acute Lymphocytic Leukemia (ALL) at a Large County Hospital

    American Society of Clinical Oncology Quality Care Symposium, 2013

  • Assessment of Absolute Lymphocyte Count (ALC) as a Predictor of Progression-Free Survival (PFS) and Overall Response Rate (ORR) in Metastatic Melanoma (MM) Patients (PTS) Treated with High-Dose Interleukin-2 (HD Il-2)

    American Society of Clinical Oncology National Meeting, 2013

  • Assessment of Absolute Lymphocyte Count (ALC) as a Predictor of Progression-Free Survival (PFS) and Overall Response Rate (ORR) in Metastatic Melanoma (MM) Patients (PTS) Treated with High-Dose Interleukin-2 (HD Il-2)

    ASCO Annual Meeting, 2013

  • How Have We Diagnosed Early-Stage Lung Cancer Without Radiographic Screening? A Contemporary Single-Center Experience

    PLoS ONE, 2012

  • Socioeconomic Disparities in Lung Cancer Treatment and Outcomes Persist Within a Single Academic Medical Center

    Clinical Lung Cancer, 2012

  • Recent Advances and Emerging Therapies in the Systemic Treatment of Metastatic Melanoma

    Clinical Oncology News, 2012

  • A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas

    International Journal of Surgical Oncology, 2012

  • Presentation of Early-Stage Non-Small Cell Lung Cancer (NSCLC) Without Radiographic Screening: End of an Era?

    ASCO Annual Meeting, 2011

  • The Influence of Medical Comorbidities on the Presentation and Outcome of Stage I-III Non-Small Cell Lung Cancer

    2010 ASCO Annual Meeting, 2010

  • The Association Between Clinical Characteristics, Treatment Modality and Outcomes of Non-Small Cell Lung Cancer

    ASCO Annual Meeting, 2009

  • The Association Between Clinical Characteristics, Treatment Modality and Outcomes of Non-Small Cell Lung Cancer

    American Society of Clinical Oncology National Meeting– Orlando, FL, 2009

  • Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity

    Journal of Thoracic Oncology, 2009

  • The Effect of a Disease Management Algorithm and Dedicated Postacute Coronary Syndrome Clinic on Achievement of Guideline Compliance: Results from the Parkland Acute Coronary Event Treatment Study

    Journal of Investigative Medicine, 2008

  • The Association Between Patient Characteristics, Health Care System Characteristics and Clinical Outcomes in Non-Small Cell Lung Cancer

    Eastern Cooperative Oncology Group National Meeting, 2008

  • The Effect of a Disease Management Algorithm and Dedicated Post-ACS Clinic on Achievement of Guideline Compliance: Results from the Parkland Acute Coronary Event Treatment Study

    Sixth Annual University of Texas Southwestern Cardiovascular Symposium – Dallas, TX, 2006

  • Increasing Use of Evidence-Based Therapies Across Ethnic Groups After Acute Coronary Events: Observations from the Parkland Acute Coronary Event Treatment Study

    Fifth Annual University of Texas Southwestern Cardiovascular Symposium – Dallas, TX, 2005